menu
    • menu
    [{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Neurology","graph2":"IND Enabling","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PharmAla Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"University of Sydney","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ University of Sydney"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"UT Health San Antonio","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Agreement","leadProduct":"Midomafetamine","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ UT Health San Antonio","highestDevelopmentStatusID":"7","companyTruncated":"PharmAla Biotech \/ UT Health San Antonio"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PharmAla Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PharmAla Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PharmAla Biotech

    Menu

    PharmAla Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PharmAla Biotech

                            Canada arrow
                            Excipient World
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : UT Health San Antonio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PharmAla to Supply STRONG STAR at UT Health San Antonio

                            Details : PharmAla develop a new 20mg clinical drug product dose of its LaNeo™ MDMA to examine tolerability of MDMA in Schizophrenia.

                            Product Name : ALA-002

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 27, 2025

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : UT Health San Antonio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $0.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            PharmAla Announces Private Placement and Concurrent Debt Settlement

                            Details : Net proceeds will support development of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine) for treating PTSD and social anxiety in autistic adults.

                            Product Name : ALA-002

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $0.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.7 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            PharmAla Closes Private Placement and Concurrent Debt Settlement

                            Details : Net proceeds will support development of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine) for treating PTSD and social anxiety in autistic adults.

                            Product Name : ALA-002

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            April 19, 2024

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : $0.7 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PharmAla Biotech

                            Canada arrow
                            Excipient World
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $5.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            PharmAla Biotech Announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000

                            Details : The Company intends to use the net proceeds to fund phase 2 clinical trials of the Company’s patented ALA series of molecules including, ALA-002, an oral, small molecule drug being developed for the treatment of social anxiety disorder and post-traumat...

                            Product Name : ALA-002

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            December 06, 2023

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $5.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PharmAla Biotech

                            Canada arrow
                            Excipient World
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            Excipient World
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : University of Sydney

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney

                            Details : The agreement aims for the clinical phase development of ALA-002 which under investigation for the treatment of post-traumatic stress disorder (PTSD) and social anxiety in autistic adults.

                            Product Name : ALA-002

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : University of Sydney

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

                            Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            March 02, 2023

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed

                            PharmAla Biotech

                            Canada arrow
                            ISPE Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

                            Details : PharmAla’s goal is to bring ALA-002 into the clinic as a treatment for disorders in adults diagnosed with Autism Spectrum Disorder (ASD). ALA-002 was tested not only in general population research, but also in generally accepted autism mouse models.

                            Product Name : ALA-002

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            February 11, 2022

                            Lead Product(s) : Midomafetamine

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth